SCHEMBL4068045

SCHEMBL4068045

Clc1ccc(N2C[CH]CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
ADRB1 P08588 1/20 0.50
HTR3A P46098 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
CHIA Q9BZP6 1/20 0.43
LTA4H P09960 2/20 0.42
DRD4 P21917 2/20 0.42
ALDH1A1 P00352 4/20 0.41
AKR1C3 P42330 3/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 3/20 0.40
KDM4E B2RXH2 3/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069242 0.88 HTR3E (0.47) HTR3EHTR3BADRB1HTR3AHTR3D
SCHEMBL4074886 0.86 HTR3E (0.59) HTR3EHTR3BADRB1HTR3AHTR3D
SCHEMBL5276484 0.81 SIGMAR1 (0.48) HTR3EHTR3BADRB1HTR3AHTR3D
SCHEMBL6399527 0.78 MAPT (0.46) DRD4ALDH1A1LMNAMAPTKDM4E
SCHEMBL2127395 0.78 MAPT (0.52) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL4067323 0.78 MAPT (0.50) DRD4ALDH1A1AKR1C3LMNAHPGD
SCHEMBL4071866 0.78 ADRB1 (0.50) ADRB1ALDH1A1AKR1C3LMNAHPGD
SCHEMBL150538 0.77 SIGMAR1 (0.46) HTR3EHTR3BADRB1HTR3AHTR3D
SCHEMBL11771698 0.77 HTR3E (0.58) HTR3EHTR3BADRB1HTR3AHTR3D
SCHEMBL4067588 0.76 HTR3E (0.56) HTR3EHTR3BADRB1HTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103328446-A Novel 4-amino-n-hydroxy-benzamides for the treatment of cancer HOFFMANN LA ROCHE 2013-09-25 CN claimed
CN-1149191-C Azetidine derivatives, Preparation and medicines containing them ���ĵ�˹ҩ��ɷ����޹�˾ 2004-05-12 CN claimed
CN-1473040-A Association and medicinal composition of CB1 receptor antagonist and sibutramin for treating obesity ���ĵ�˹ҩ��ɷ����޹�˾ 2004-02-04 CN claimed
CN-1316991-A Azetidine derivatives, preparation and medicines containing them AVENTIS PHARMA SA (FR) 2001-10-10 CN claimed
CN-103328446-A Novel 4-amino-n-hydroxy-benzamides for the treatment of cancer HOFFMANN LA ROCHE 2013-09-25 CN disclosed
CN-103068830-A Arginase inhibitors and therapeutic uses thereof MARS INC 2013-04-24 CN disclosed
EP-1415986-B1 SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS BANYU PHARMA CO LTD (JP) 2009-04-08 EP disclosed
CN-100409845-C Combination form of CB1 receptor antagonist and sibutramine, pharmaceutical composition thereof and application of pharmaceutical composition in preparation of drugs for treating obesity AVENTIS PHARMA SA (FR) 2008-08-13 CN disclosed
US-7205417-B2 Spiro compounds BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-04-17 US disclosed
CN-1538956-A Spiro compounds ������ҩ��ʽ���� 2004-10-20 CN disclosed
CN-1149191-C Azetidine derivatives, Preparation and medicines containing them ���ĵ�˹ҩ��ɷ����޹�˾ 2004-05-12 CN disclosed
CN-1473040-A Association and medicinal composition of CB1 receptor antagonist and sibutramin for treating obesity ���ĵ�˹ҩ��ɷ����޹�˾ 2004-02-04 CN disclosed
CN-1316991-A Azetidine derivatives, preparation and medicines containing them AVENTIS PHARMA SA (FR) 2001-10-10 CN disclosed